DengYueMed is a China-focused pharmaceutical export wholesaler headquartered in Hong Kong. We offer more than 30,000 types of medicines, covering Chinese innovative drugs, oncology, hematology, orphan drugs, and a wide range of hospital-needed pharmaceuticals. Through our extensive international trade network, we are committed to ensuring the global supply of high-quality medicines to meet the healthcare needs of different regions. We consistently prioritize drug safety, efficacy, and stable quality, ensuring that all our products comply with international certification standards.
-
7 Articoli
-
2 Foto
-
0 Video
-
Altre informazioni
-
08/09/2005
-
Seguito da 1 people
Aggiornamenti recenti
-
A Glimmer of Hope: Navigating Chronic Illness in the Era of 2026's Top Drugs and China's Emerging InnovationsLiving with a chronic condition like diabetes, obesity, or cancer can turn everyday life into a relentless grind—the prick of needles for blood checks, the disheartening scale readings that refuse to budge, or the shadow of uncertainty hanging over every medical appointment. I've heard from so many who feel this way: the quiet resignation to a body that seems to betray them, the fear of...0 Commenti 0 condivisioni 162 Views 0 AnteprimaEffettua l'accesso per mettere mi piace, condividere e commentare!
-
Renewed Hope: China's Advancing ADC Therapies and the 2025 Approvals Illuminating the Path for Cancer WarriorsIn a world where cancer remains a formidable enemy, every scientific advance becomes a beacon of hope for millions of patients fighting day by day. As an editor at DengYueMed, a company that, with its commitment to excellence, innovation, sustainability, and social responsibility—built on the foundations of quality, compliance, and integrity—actively participates in the global...0 Commenti 0 condivisioni 121 Views 0 Anteprima
-
China's Innovative Drug Export: Accelerating a New Era of GlobalizationIn the pharmaceutical landscape of 2025, Chinese innovative drug companies are advancing onto the international stage at an unprecedented pace. Over the past 24 hours, several key developments have highlighted this trend, showcasing not only the innovative prowess of Chinese firms but also the deepening of global collaborations. According to the latest drug price registration system launched by...0 Commenti 0 condivisioni 220 Views 0 Anteprima
-
0 Commenti 0 condivisioni 133 Views 0 Anteprima
-
Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List PriceIonis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024. First FDA-Approved Olezarsen Therapy for...0 Commenti 0 condivisioni 1K Views 0 Anteprima
-
PARSABIV (Etelcalcetide Hydrochloride Injection) – Mechanism of Action and DosageBelow is a detailed description of the mechanism of action and dosage of PARSABIV (Etelcalcetide Hydrochloride Injection): Mechanism of Action PARSABIV is a synthetic calcimimetic peptide drug. Its active ingredient, etelcalcetide, specifically binds to and activates the calcium-sensing receptors (CaSR) on the surface of parathyroid cells. By mimicking the physiological effects of increased...0 Commenti 0 condivisioni 1K Views 0 Anteprima
-
0 Commenti 0 condivisioni 463 Views 0 Anteprima
Altre storie